Dose Insider / Glossary / Prior authorization

Prior authorizationThe approval a plan requires before it pays for a GLP-1

Updated November 20, 2026 路 3 min read 路 HealthCare.gov glossary; KFF Medicaid GLP-1 survey, January 2026; Nyambod 2026 (Cureus); Medicare.gov

Prior authorization is approval from a health plan that may be required before a person gets a service or fills a prescription, for the plan to cover it.1 For GLP-1 medicines it is common. KFF's survey of state Medicaid programs found that when GLP-1s are covered, they are typically subject to controls such as prior authorization, which can further limit access.2

16Covering, October 2025, state Medicaid and GLP-1s
State Medicaid and GLP-1sPrograms covering GLP-1s for obesity, of 51COVERINGOctober 202516January 2026132025 TO 2026Withdrew coverage5Never covered34State Medicaid and GLP-1sPrograms covering GLP-1s for obesity, of 51COVERINGOctober 202516January 2026132025 TO 2026Withdrew coverage5Never covered34

Where covered, prior authorization is the usual condition.

On this page

How it works

Without that approval, the plan does not cover the prescription. A related tool is the formulary, the list of prescription drugs a plan covers, also called a drug list.1,3 Criteria differ from plan to plan. A 2026 study of Medicaid notes that earlier research found wide variation in prior authorization criteria between states.4

What the numbers show in Medicaid

KFF counted 16 state Medicaid programs covering GLP-1s for obesity treatment in October 2025. North Carolina dropped coverage that month because of a budget stalemate and restored it in December, and by January 2026 the count was 13, counting coverage under fee-for-service.2

The 2026 study followed all 51 programs, the 50 states and the District of Columbia. 17 covered at least one GLP-1 for obesity at some point in the study period, and 34 never covered these drugs. 5 withdrew coverage: North Carolina in October 2025, before reinstating it on December 12, and California, New Hampshire, Pennsylvania and South Carolina on January 1, 2026. Twelve kept coverage through the first quarter of 2026, including Massachusetts, whose withdrawal took effect in July 2026. Even where coverage existed, earlier studies had found use below 5% of eligible people.4 When coverage was withdrawn, the effect was large:4

Why obesity coverage is optional

State Medicaid programs must cover nearly all FDA-approved drugs, but a long-standing exception in the law lets states choose whether to cover weight-loss drugs; KFF describes it as a statutory exception, written into the law itself. So GLP-1s for obesity are optional for states. Coverage is required for the approved uses in diabetes, in heart disease for Wegovy since March 2024, and in moderate to severe obstructive sleep apnea with obesity for Zepbound since December 2024.2

Cost is the pressure behind the controls. KFF reports that Medicaid's gross spending on GLP-1s rose ninefold, from about $1 billion in 2019 to almost $9 billion in 2024, with gross spending per prescription reaching $1,000 in 2024. It expects coverage to keep changing as states respond to budget challenges, to federal Medicaid spending cuts in the 2025 reconciliation law, and to a new federal model called BALANCE.2

In Medicare

Medicare.gov describes Medicare GLP-1 Bridge, which gives access to certain GLP-1 drugs for weight loss to people with Part D drug coverage who are not already getting them covered by Part D and who meet other requirements. Those who qualify pay $50 for a one-month supply.5

In practice

When a plan will not pay, the makers sell self-pay versions of the approved drugs; our page on GLP-1 costs without insurance compares them.

Sources

  1. HealthCare.gov. Prior authorization. Glossary, Centers for Medicare & Medicaid Services, read November 20, 2026. healthcare.gov
  2. Williams E. Medicaid coverage of and spending on GLP-1s. KFF, January 16, 2026. kff.org
  3. HealthCare.gov. Formulary. Glossary, Centers for Medicare & Medicaid Services, read November 20, 2026. healthcare.gov
  4. Nyambod FT, Msemakweli JG, Onesphore M, et al. Medicaid coverage withdrawal and dispensing of glucagon-like peptide-1 receptor agonists for obesity. Cureus 2026;18:e119224. doi:10.7759/cureus.119224
  5. Medicare.gov. Obesity behavioral therapy. Centers for Medicare & Medicaid Services, read November 20, 2026. medicare.gov

Related analyses

Log your weight and BMI over time, so the history is ready if your plan asks for it.

Open Dose Insider